Ozempic Gastroparesis Settlement: Legal Options for Texas Patients

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Information to Targeted Legal Inquiry

For decades, the domain of general health and science information has served as a foundational resource for public understanding of medical conditions, treatment options, and preventive care. This legacy context has empowered individuals to make informed decisions about their well-being, often by translating complex biomedical concepts into accessible knowledge. Within this broad framework, discussions of metabolic health and pharmaceutical interventions have naturally evolved, reflecting ongoing advances in therapeutic science. As public awareness of medication-related side effects has grown, a specific area of concern has emerged: the potential link between certain widely prescribed drugs and gastrointestinal complications. Among these, the class of glucagon-like peptide-1 receptor agonists—used for managing type 2 diabetes and weight loss—has drawn particular attention. Reports of delayed gastric emptying, or gastroparesis, in patients using these medications have prompted a shift from general health education to more targeted legal and medical inquiries. This transition is exemplified by the query regarding Ozempic and gastroparesis settlements in Texas. Here, the legacy of general health information provides the necessary backdrop for understanding how a patient’s therapeutic exposure to Ozempic may intersect with the risk of developing gastroparesis. The pivot from broad health literacy to a specific occupational exposure concern—in this case, the patient’s exposure to the drug—reflects a natural progression from awareness to actionable legal recourse.

Find Out If You Qualify for Compensation →

Understanding Ozempic and Its Gastrointestinal Risks

Ozempic, the brand name for semaglutide, is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the management of type 2 diabetes. Among its known adverse effects, gastrointestinal complications are prominent, and emerging evidence links the drug to gastroparesis—a condition characterized by delayed gastric emptying without mechanical obstruction. This section examines the clinical presentation of gastroparesis, the pharmacological profile of Ozempic, mechanistic pathways connecting the drug to this condition, and risk considerations for affected patients, particularly in the context of potential settlements in Texas. Gastroparesis presents with symptoms such as nausea, vomiting, early satiety, postprandial fullness, bloating, and abdominal pain. Diagnosis typically involves gastric emptying scintigraphy, which measures the rate at which food leaves the stomach. The condition can lead to malnutrition, dehydration, and significant impairment in quality of life.

Clinical Evidence Linking Ozempic to Gastroparesis

In the context of Ozempic use, gastrointestinal adverse reactions are well-documented. In placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo: placebo 15.3%, Ozempic 0.5 mg 32.7%, and Ozempic 1 mg 36.4% (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additionally, more patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These data indicate a dose-dependent increase in gastrointestinal side effects, which may include gastroparesis.

Mechanisms and Label Considerations

The pharmacology of Ozempic involves activation of GLP-1 receptors, which slow gastric emptying as part of their mechanism to regulate postprandial glucose levels. This physiological effect can become pathological in some patients, leading to gastroparesis. Mechanistically, GLP-1 receptor agonists like semaglutide inhibit gastric motility by acting on vagal afferent nerves and smooth muscle cells, potentially causing prolonged gastric stasis. While the label does not explicitly list gastroparesis as an adverse reaction, it reports other gastrointestinal conditions such as dyspepsia (1.9% placebo, 3.5% Ozempic 0.5 mg, 2.7% Ozempic 1 mg), eructation (0% placebo, 2.7% Ozempic 0.5 mg, 1.1% Ozempic 1 mg), flatulence (0.8% placebo, 0.4% Ozempic 0.5 mg, 1.5% Ozempic 1 mg), gastroesophageal reflux disease (0% placebo, 1.9% Ozempic 0.5 mg, 1.5% Ozempic 1 mg), and gastritis (0.8% placebo, 0.8% Ozempic 0.5 mg, 0.4% Ozempic 1 mg) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These conditions share overlapping symptoms with gastroparesis, suggesting a spectrum of GLP-1-induced gastrointestinal dysfunction.

Legal Context for Texas Patients

Risk considerations for patients who develop gastroparesis after Ozempic use center on the adequacy of warnings. The Ozempic label includes warnings about serious hypersensitivity reactions such as anaphylaxis and angioedema (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166), but it does not specifically warn about gastroparesis. This omission may be critical for patients who experience severe, persistent symptoms. The timeline between exposure and documented harm is variable; gastrointestinal adverse reactions often occur during dose escalation, but gastroparesis may develop after prolonged use. Patients who discontinue Ozempic due to gastrointestinal issues may still experience lingering symptoms, raising questions about causality and recovery. For affected patients in Texas, settlement-related considerations involve proving that Ozempic caused or contributed to gastroparesis. Legal claims may hinge on whether the manufacturer provided adequate warnings about the risk of gastroparesis. Given the absence of a specific warning in the label, plaintiffs may argue that the drug's known gastrointestinal effects, including delayed gastric emptying, should have prompted more explicit communication. Settlement amounts could depend on the severity of harm, including medical expenses, lost wages, and pain and suffering. Patients should document their symptom onset relative to Ozempic use, including dates of dose changes, and seek medical confirmation of gastroparesis through gastric emptying studies.

Summary and Next Steps

In summary, Ozempic is associated with a high incidence of gastrointestinal adverse reactions, including conditions that mimic or lead to gastroparesis. The mechanistic link through GLP-1 receptor activation supports a plausible causal pathway. However, the lack of a specific gastroparesis warning in the label may affect risk assessment for patients and legal outcomes. Those affected should consult both medical and legal professionals to evaluate their individual circumstances. References (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166)

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the link between Ozempic and gastroparesis?

Ozempic (semaglutide) is a GLP-1 receptor agonist that slows gastric emptying as part of its mechanism. This can become pathological, leading to gastroparesis—a condition of delayed gastric emptying without obstruction. Clinical trials show high rates of gastrointestinal adverse reactions, including nausea, vomiting, and dyspepsia, which overlap with gastroparesis symptoms. The label does not specifically warn about gastroparesis, but the mechanistic link is plausible.

Can I file a lawsuit in Texas for Ozempic-related gastroparesis?

Yes, Texas patients who developed gastroparesis after using Ozempic may have legal claims based on inadequate warnings. The manufacturer did not specifically warn about gastroparesis, despite known gastrointestinal effects. To pursue a settlement, you need medical documentation of gastroparesis (e.g., gastric emptying study) and evidence linking it to Ozempic use. Consult a Texas injury lawyer experienced in pharmaceutical litigation.

What evidence is needed for an Ozempic gastroparesis claim?

Key evidence includes: medical records showing a gastroparesis diagnosis (gastric emptying scintigraphy), prescription records documenting Ozempic use, symptom onset timeline relative to medication, and any discontinuation due to side effects. Also, document dose changes and other medications. An attorney can help gather expert testimony on causation and the adequacy of warnings.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Ozempic Label - DailyMed

Find Out If You Qualify for Compensation

Statutes of limitations can limit the time you have to file a claim. A records screening is free and confidential.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.